In 2016, 29 444 people were newly diagnosed with HIV in the 31 countries of the EU/EEA, which equals a rate of 5.7 cases per 100 000 population

The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, with a focus on the countries of the European Union (EU) and the European Economic Area (EEA).

This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.

This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.

The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.

This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.

HIV infection remains a major public health concern in EU/EEA countries, with approximately 30 000new infections reported each year. In contrast, the overall number of AIDS cases has continued tosteadily decline thanks to the growing use of effective antiretroviral treatment.

This ECDC series provides comprehensive guides to the effective use of digital platforms for STI/HIV prevention among MSM in the EU/EEA.